Medsyn Biopharma

Medsyn Biopharma is a pre-clinical stage biotechnology company focused on developing and commercializing novel small molecule therapeutics for the treatment of cancer and other diseases. Co-founded by researchers from the University of Michigan, the company leverages its proprietary Domain-ALTeration Chimeras (DALTACs) platform to rewire disease-defining protein complexes by enforcing non-native domain-domain interactions. Medsyn's pipeline includes first-in-class DALTAC programs targeting the androgen receptor (AR) and p300/CBP for prostate cancer, as well as Polycomb repressive complex 2 (PRC2) inhibitors. Additionally, the company is developing covalent small-molecule inhibitors targeting the menin-MLL protein-protein interaction for acute leukemia.